{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:55:19Z","timestamp":1777485319881,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,17]]},"DOI":"10.7759\/cureus.35116","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T20:39:45Z","timestamp":1676666385000},"source":"Crossref","is-referenced-by-count":10,"title":["Procedure, Screening, and Cost of Fecal Microbiota Transplantation"],"prefix":"10.7759","author":[{"given":"Austin B","family":"Wynn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garet","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2016.09.012","article-title":"Fecal microbiota transplantation","volume":"46","author":"Vindigni SM","year":"2017","unstructured":"Vindigni SM, Surawicz CM. Fecal microbiota transplantation. Gastroenterol Clin North Am. 2017, 46:171-185. 10.1016\/j.gtc.2016.09.012","journal-title":"Gastroenterol Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2018.0328","article-title":"Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness","volume":"32","author":"Ramai D","year":"2019","unstructured":"Ramai D, Zakhia K, Ofosu A, Ofori E, Reddy M. Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. Ann Gastroenterol. 2019, 32:30-38. 10.20524\/aog.2018.0328","journal-title":"Ann Gastroenterol"},{"key":"ref3","unstructured":"Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation - screenign and testing of stool donors for multi-drug resistant organisms. (2019). Accessed. January 30, 2023: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/information-pertaining-additional-safety-p...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aap9489","article-title":"Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant","volume":"10","author":"Taur Y","year":"2018","unstructured":"Taur Y, Coyte K, Schluter J, et al.. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 2018, 10:eaap9489. 10.1126\/scitranslmed.aap9489","journal-title":"Sci Transl Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-022-12154-z","article-title":"The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model","volume":"106","author":"Xu Q","year":"2022","unstructured":"Xu Q, Zhang S, Quan J, et al.. The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model. Appl Microbiol Biotechnol. 2022, 106:6689-6700. 10.1007\/s00253-022-12154-z","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2084306","article-title":"Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection","volume":"14","author":"Wei S","year":"2022","unstructured":"Wei S, Bahl MI, Baunwall SM, Dahlerup JF, Hvas CL, Licht TR. Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection. Gut Microbes. 2022, 14:2084306. 10.1080\/19490976.2022.2084306","journal-title":"Gut Microbes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16309","article-title":"Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections","volume":"53","author":"Rode AA","year":"2021","unstructured":"Rode AA, Chehri M, Krogsgaard LR, et al.. Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections. Aliment Pharmacol Ther. 2021, 53:999-1009. 10.1111\/apt.16309","journal-title":"Aliment Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.12.029","article-title":"Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection","volume":"18","author":"Cheng YW","year":"2020","unstructured":"Cheng YW, Phelps E, Nemes S, et al.. Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection. Clin Gastroenterol Hepatol. 2020, 18:2234-2243. 10.1016\/j.cgh.2019.12.029","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.08.047","article-title":"Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT","volume":"174","author":"Suez J","year":"2018","unstructured":"Suez J, Zmora N, Zilberman-Schapira G, et al.. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018, 174:1406-1423. 10.1016\/j.cell.2018.08.047","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2050640616678099","article-title":"Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection","volume":"5","author":"van Beurden YH","year":"2017","unstructured":"van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United European Gastroenterol J. 2017, 5:868-879. 10.1177\/2050640616678099","journal-title":"United European Gastroenterol J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2017.1353848","article-title":"The risk of inflammatory bowel disease flares after fecal microbiota transplantation: systematic review and meta-analysis","volume":"8","author":"Qazi T","year":"2017","unstructured":"Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: systematic review and meta-analysis. Gut Microbes. 2017, 8:574-588. 10.1080\/19490976.2017.1353848","journal-title":"Gut Microbes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17077","article-title":"Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial","volume":"318","author":"Kao D","year":"2017","unstructured":"Kao D, Roach B, Silva M, et al.. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017, 318:1985-1993. 10.1001\/jama.2017.17077","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9020358","article-title":"An oral FMT capsule as efficient as an enema for microbiota reconstruction following disruption by antibiotics, as assessed in an in vitro human gut model","volume":"9","author":"Verdier C","year":"2021","unstructured":"Verdier C, Denis S, Gasc C, et al.. An oral FMT capsule as efficient as an enema for microbiota reconstruction following disruption by antibiotics, as assessed in an in vitro human gut model. Microorganisms. 2021, 9:358. 10.3390\/microorganisms9020358","journal-title":"Microorganisms"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000415","article-title":"Fecal microbial therapy: promises and pitfalls","volume":"59","author":"Merenstein D","year":"2014","unstructured":"Merenstein D, El-Nachef N, Lynch SV. Fecal microbial therapy: promises and pitfalls. J Pediatr Gastroenterol Nutr. 2014, 59:157-161. 10.1097\/MPG.0000000000000415","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000405","article-title":"Donor recruitment for fecal microbiota transplantation","volume":"21","author":"Paramsothy S","year":"2015","unstructured":"Paramsothy S, Borody TJ, Lin E, et al.. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis. 2015, 21:1600-1606. 10.1097\/MIB.0000000000000405","journal-title":"Inflamm Bowel Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2017.1286006","article-title":"Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review","volume":"8","author":"Woodworth MH","year":"2017","unstructured":"Woodworth MH, Carpentieri C, Sitchenko KL, Kraft CS. Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review. Gut Microbes. 2017, 8:225-237. 10.1080\/19490976.2017.1286006","journal-title":"Gut Microbes"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1599","article-title":"Cost-effectiveness of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection: a literature review","volume":"9","author":"Arbel LT","year":"2017","unstructured":"Arbel LT, Hsu E, McNally K. Cost-effectiveness of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection: a literature review. Cureus. 2017, 9:e1599. 10.7759\/cureus.1599","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.09.025","article-title":"Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection","volume":"81","author":"Shaffer SR","year":"2020","unstructured":"Shaffer SR, Witt J, Targownik LE, et al.. Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. J Infect. 2020, 81:758-765. 10.1016\/j.jinf.2020.09.025","journal-title":"J Infect"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz318","article-title":"Cost-effectiveness of treatment regimens for Clostridioides difficile infection: an evaluation of the 2018 Infectious Diseases Society of America Guidelines","volume":"70","author":"Rajasingham R","year":"2020","unstructured":"Rajasingham R, Enns EA, Khoruts A, Vaughn BP. Cost-effectiveness of treatment regimens for Clostridioides difficile infection: an evaluation of the 2018 Infectious Diseases Society of America Guidelines. Clin Infect Dis. 2020, 70:754-762. 10.1093\/cid\/ciz318","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/128494-procedure-screening-and-cost-of-fecal-microbiota-transplantation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:08Z","timestamp":1707508328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/128494-procedure-screening-and-cost-of-fecal-microbiota-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.35116","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}